Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer

  • STATUS
    Recruiting
  • End date
    May 1, 2023
  • participants needed
    39
  • sponsor
    Mayo Clinic
Updated on 22 March 2022
ct scan
platelet count
cancer
hodgkin's disease
rituximab
metastatic disease
measurable disease
breast cancer
international normalized ratio
metastasis
neutrophil count
pembrolizumab
trastuzumab
nivolumab
adenocarcinoma
stage iv breast cancer
breast adenocarcinoma
t-cell lymphoma
obinutuzumab

Summary

This pilot phase I trial studies the side effects of direct tumor microinjection and fludeoxyglucose F-18 positron emission tomography (FDG-PET) in testing drug sensitivity in patients with non-Hodgkin lymphoma, Hodgkin lymphoma, or stage IV breast cancer that has returned after a period of improvement or does not respond to treatment. Injecting tiny amounts of anti-cancer drugs directly into tumors on the skin or in lymph nodes and diagnostic procedures, such as FDG-PET, may help to show which drugs work better in treating patients with non-Hodgkin lymphoma, Hodgkin lymphoma, or breast cancer.

Description

PRIMARY OBJECTIVE:

I. To assess the safety of in vivo in host drug sensitivity testing in patients with breast cancer and patients with lymphoma (nodal, extranodal masses, or cutaneous lesions).

SECONDARY OBJECTIVES:

I. To assess the feasibility of in vivo in host drug sensitivity testing in this patient population.

II. To identify targeted therapies with potential activity in relapsed lymphoma and metastatic breast cancer.

III. To evaluate the adverse event profile within each patient population.

CORRELATIVE OBJECTIVES:

I. To assess for apoptosis in response to intratumoral injection using known biomarkers (e.g., by morphology, Ki-67, caspace-3 assay as a marker of early apoptosis).

II. To evaluate intratumoral biomarkers, intratumoral cell populations, and distribution, identify potential biomarkers that correlate with response to therapy based on individual therapies.

OUTLINE

Patients undergo FDG-PET and receive saline intralesionally on day 1. Patients also receive up to five additional injections of gemcitabine hydrochloride, romidepsin, belinostat, carfilzomib, copanlisib hydrochloride, nivolumab, trastuzumab, daratumumab, obinutuzumab, pembrolizumab, or rituximab intralesionally per investigator on day 1. Beginning 5 days later, patients with nodal/extranodal mass undergo restaging FDG-PET and biopsy (if clinically feasible). Within 3-7 days, patients with cutaneous disease undergo restaging photography and biopsy.

After completion of study treatment, patients are followed up at 3 months.

Details
Condition Breast Adenocarcinoma, Metastatic Breast Carcinoma, Recurrent Breast Carcinoma, Recurrent Hodgkin Lymphoma, Recurrent Mycosis Fungoides, Recurrent Non-Hodgkin Lymphoma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Breast Carcinoma, Refractory Hodgkin Lymphoma, Refractory Mycosis Fungoides, Refractory Nodal Marginal Zone Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Stage IV Breast Cancer AJCC v6 and v7
Treatment Rituximab, laboratory biomarker analysis, gemcitabine hydrochloride, positron emission tomography, Trastuzumab, Pembrolizumab, Obinutuzumab, Nivolumab, romidepsin, Fludeoxyglucose F-18, Saline, Daratumumab, Carfilzomib, Belinostat, Copanlisib Hydrochloride
Clinical Study IdentifierNCT03432741
SponsorMayo Clinic
Last Modified on22 March 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Age >= 18 years
Histologically proven of relapsed or refractory
Non-Hodgkin lymphoma (NHL) or Hodgkin lymphoma (HL) nodal or extranodal mass OR
Cutaneous T-cell lymphoma (CTCL) including mycosis fungoides (MF), as well as transformed MF OR
Breast adenocarcinoma with nodal or cutaneous metastases (stage 4)
NOTE: Patients must be refractory to or intolerant of existing therapy(ies) known to provide clinical benefit for their condition
NOTE: The patient must not be a candidate for any curative therapy or any known life-prolonging therapy
Cohort I: For nodal/extranodal mass, presence of lesions that are amenable for
injections as determined by interventional radiology
NOTE: Nodal or extranodal mass must be palpable and easily accessible; masses such as mediastinum, retroperitoneum, within solid organs, spinal sites, central nervous system (CNS) sites, etc., are NOT allowed
Measurable disease
For nodal or extranodal disease (lymphoma or breast): must have at least 2 lesions that are >= 20 mm (2.0 cm) in the longest diameter by physical exam and/or on cross-sectional imaging and measurable in two perpendicular dimensions per computed tomography PET-computed tomography (CT); For Cohort I, the lesions must be amenable to intralesional injections as determined by interventional radiology (including tumors that can be safely accessed using imaging guidance and treated with minimal risk to adjacent structures)
For cutaneous lesions (lymphoma or breast): at least two visible, non-infected skin lesions that are greater than 1 cm and are amenable to intralesional injection as determined by investigator
Candidate for further therapy and able to wait 7 days prior to start of next systemic
Absolute neutrophil count (ANC) >= 1000/mm^3 (obtained =< 14 days prior to registration)
therapy
Platelet count >= 50,000/mm^3 (obtained =< 14 days prior to registration)
International normalized ratio (INR)/prothrombin time (PT) =< 1.5 (obtained =< 14 days prior to registration)
Negative serum or urine pregnancy test done =< 7 days prior to registration, for persons of childbearing potential only
Provide written informed consent
Willing to return to enrolling institution for follow-up
Willing to provide tissue samples for correlative research purposes

Exclusion Criteria

Any of the following
Pregnant persons
Nursing persons
Persons of childbearing potential who are unwilling to employ adequate contraception
Systemic corticosteroids between pre-PET and post-PET evaluation and biopsy
Prohibited treatments and or therapies
Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment
Autologous stem cell transplant (ASCT) =< 12 weeks prior to registration
of the investigator, would make the patient inappropriate for entry into this
Prior chemotherapy =< 2 weeks prior to registration
study or interfere significantly with the proper assessment of safety and
Prior treatment with nitrosureas =< 4 weeks prior to registration
toxicity of the prescribed regimens
Therapeutic anticancer antibodies =< 2 weeks prior to registration
Radio- or toxin immunoconjugates =< 4 weeks prior to registration
Radiation therapy to the injected area =< 2 weeks prior to registration
Major surgery =< 2 weeks prior to registration
Requires anticoagulation that cannot be discontinued prior to biopsy
Note: Exception if able to hold antiplatelet agents 7 days prior to the injections and biopsy
NOTE: Low molecular weight heparin (LMWH) will be allowed for bridging if on warfarin
NOTE: Heparin for line patency without detectable lab abnormalities for coagulation will be allowed
Receiving any other investigational agent which would be considered as a treatment for
the primary neoplasm
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note